[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-200537-105":53,"doc-detail-200537-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","sample-letter-of-medical-necessity-provide-medical-necessity-for-insurance-coverage","Sample Letter of Medical Necessity - Provide Medical Necessity for Insurance Coverage","","Medical necessity letter template for insurance coverage requests, addressed to an insurer on behalf of a specific patient. Includes placeholders for patient demographics, policy and ID information, and prescribing details for VYJUVEK (beremagene geperpavec-svdt) 5x10⁹ PFU/mL tied to ICD-10-CM Q81.2. Provides FDA approval context, describes the topical, non-invasive gene therapy for DEB wounds, and outlines required sections for treatment rationale, study references, and supporting medical record highlights. Concludes with physician attestation, contact details, and enclosed prescribing information reference.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/sample-letter-of-medical-necessity-provide-medical-necessity-for-insurance-coverage/200537/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/sample-letter-of-medical-necessity-provide-medical-necessity-for-insurance-coverage/200537.png","ImageObject",442,249,{"name":88,"@type":89},"Anda","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-21","2026-09-04",true,{"@type":98,"interactionType":99,"userInteractionCount":25},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What information does the letter include for the patient and insurance claim?","Question",{"text":108,"@type":109},"The template includes placeholders for the patient’s name, ID, group number, address, policy number, and date of birth, along with the ICD-10-CM diagnosis code tied to coverage (ICD-10-CM Q81.2).","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Which treatment is the letter written to support, and what key facts are stated?",{"text":113,"@type":109},"The letter supports coverage for VYJUVEK™ (beremagene geperpavec-svdt) 5x10⁹ PFU/mL. It notes FDA approval date (May 19, 2023) and describes VYJUVEK as a non-invasive, topical, redosable gene therapy for DEB wounds and the only FDA-approved medication for that purpose.",{"name":115,"@type":106,"acceptedAnswer":116},"What sections must be completed to justify medical necessity?",{"text":117,"@type":109},"You must fill in the Treatment Rationale (response to past treatments and anticipated prognosis), reference the medical studies (including Section 14 of the attached FDA-approved Prescribing Information), and highlight key dates and entries from the medical record showing how the prescribed product will be used.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},200537,1788509256,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":25,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":9,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":125,"read_time":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Sample Letter of Medical Necessity  \n[Insurance Company] Re: [Patient Name]  \n[Address] [Policy \\#]  \n[City, State, Zip] [DOB]  \n[Address]  \n[City, State, Zip]  \nTo Whom It May Concern:  \nI am writing on behalf of my patient, [Patient Name, ID, and Group Number] for the coverage of VYJUVEK ™ (beremagene geperpavec-svdt) 5x10⁹ PFU/mL associated with ICD-10-CM Q81 .2. This letter of medical necessity includes the patient’s relevant past medical history, overview of prior care delivered, treatment rationale and supporting medical necessity data.  \nVYJUVEK was approved by the U.S. Food and Drug Administration on Friday, May 19th, 2023. VYJUVEK is a non-invasive, topical, redosable gene therapy that was systematically studied in patients with Dystrophic Epidermolysis Bullosa. VYJUVEK is the only FDA-approved medication for the treatment of DEB wounds.  \nTreatment Rationale:  \n[Provide information on patient response to past treatments, anticipated prognosis, and rationale for the currently prescribed product] .  \nOutline of Medical Studies:  \n[Please see Section 14 of the attached FDA approved Prescribing Information. vyjuvek-us-pi.pdf ( [krystallabel.com](krystallabel.com))]  \nMedical Record Information:  \n[Highlight key dates and entries of the medical record how the currently prescribed product is used] .  \nPer the included medical information, it is my professional opinion that the currently prescribed product is medically necessary in treating the patient. Please call my office at [Office Phone Number] if I can provide further information or speak with a review board to obtain coverage.  \nSincerely,  \n[Physician Name and Signature]  \n[Phone Number]  \nEnclosure: [FDA approved Prescribing Information]  \nVYJ-2200032 V2 .0 June 2023","cbCaim2nWy9kPNWL","https://ap.wps.com/l/cbCaim2nWy9kPNWL","pdf",58750,"English","# Letter Header\n## Patient and Policy Details\n# Medical Necessity Statement\n## Drug and Indication Overview\n## FDA Approval Information\n# Treatment Rationale and Evidence\n## Treatment Rationale\n## Outline of Medical Studies\n## Medical Record Information\n# Physician Attestation\n## Conclusion and Contact Information\n## Enclosure","[{\"question\":\"What information does the letter include for the patient and insurance claim?\",\"answer\":\"The template includes placeholders for the patient’s name, ID, group number, address, policy number, and date of birth, along with the ICD-10-CM diagnosis code tied to coverage (ICD-10-CM Q81.2).\"},{\"question\":\"Which treatment is the letter written to support, and what key facts are stated?\",\"answer\":\"The letter supports coverage for VYJUVEK™ (beremagene geperpavec-svdt) 5x10⁹ PFU/mL. It notes FDA approval date (May 19, 2023) and describes VYJUVEK as a non-invasive, topical, redosable gene therapy for DEB wounds and the only FDA-approved medication for that purpose.\"},{\"question\":\"What sections must be completed to justify medical necessity?\",\"answer\":\"You must fill in the Treatment Rationale (response to past treatments and anticipated prognosis), reference the medical studies (including Section 14 of the attached FDA-approved Prescribing Information), and highlight key dates and entries from the medical record showing how the prescribed product will be used.\"}]","Sample Letter of Medical Necessity - Provide Medical Necessity for Insurance Coverage | PDF"]